Oriental Medicine Co-Administration with Anticancer Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer agents like tamoxifen, gefitinib, and sorafenib for treating breast, lung, and liver cancers are associated with significant side effects and drug resistance, necessitating the development of compositions that enhance efficacy while reducing toxicity and resistance.
Innovation Solution
Co-administration of traditional Oriental medicine formulations such as jaeumganghwa-tang, bojungikgi-tang, and yukmijihwang-tang with anticancer agents to improve treatment outcomes by reducing side effects and enhancing anticancer effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tamoxifen is administered to treat breast cancer, then anticancer effect is improved, but side effects including bone loss, endometrial cancer, and thromboembolism occur
Solution Approach 1:
The patent introduces oriental medicine formulations (jaeumganghwa-tang, bojungikgi-tang, yukmijihwang-tang) as intermediary substances that mediate between the anticancer agent and the patient's body. These formulations contain antioxidants and anti-inflammatory compounds that protect against tamoxifen-induced toxicity while preserving its anticancer efficacy, effectively acting as a protective buffer or mediator
2Reliability
If gefitinib is administered to treat malignant tumors, then anticancer effect is improved, but hepatotoxicity and lipid peroxidation occur
Solution Approach 1:
The patent converts the harmful effect of lipid peroxidation and hepatotoxicity into a beneficial outcome by administering oriental medicine formulations rich in antioxidants. These formulations scavenge free radicals and reduce oxidative stress, thereby converting the potentially harmful metabolic byproducts of gefitinib into manageable conditions that protect liver function
3Duration of action of stationary object
If long-term tamoxifen administration is performed, then anticancer effect is maintained, but drug resistance and recurrence occur
Solution Approach 1:
The patent applies preliminary action by administering oriental medicine formulations concurrently with tamoxifen to prevent the development of drug resistance before it occurs. The antioxidant and anti-inflammatory components prepare the cellular environment to remain sensitive to tamoxifen's anticancer effects throughout prolonged treatment periods
4Reliability
If sorafenib is administered to treat liver cancer, then anticancer effect is improved, but immunosuppression and skin reactions occur
Solution Approach 1:
The patent introduces oriental medicine formulations as intermediary agents that protect the immune system from sorafenib-induced suppression. These formulations contain immunomodulatory compounds that maintain immune function while allowing sorafenib to exert its anticancer effect on liver tumor cells
Data Source
AI summary
Provided is a composition for enhancing effects of an anticancer agent using an oriental medicine, jaeumganghwa-tang, bojungikgi-tang, or yukmijihwang-tang. More particularly, provided is a composition for treating a neoplastic disease by administering an anticancer agent into an individual, and administering an oriental medicine into the individual within 30 minutes. The composition remarkably reduces side effects occurring when the anticancer agent is administered alone by co-administration of the oriental medicine, reduces cytotoxicity, and has higher anticancer activity than that when the anticancer agent is administered alone.